Treatment of Primary Tumor and Locoregional Disease

[1]  A. Campos-Neto,et al.  Current and novel approaches to vaccine development against tuberculosis , 2012, Front. Cell. Inf. Microbio..

[2]  A. Testori,et al.  Prognosis in patients with sentinel node‐positive melanoma without immediate completion lymph node dissection , 2012, The British journal of surgery.

[3]  Joel L Cohen,et al.  Melanoma In Situ Treated Successfully Using Imiquimod After Nonclearance with Surgery: Review of the Literature , 2012, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[4]  L. Hölmich,et al.  Lymph node dissection in patients with malignant melanoma is associated with high risk of morbidity. , 2012, Danish medical journal.

[5]  M. Hočevar,et al.  Adjuvant radiotherapy for palpable melanoma metastases to the groin: when to irradiate? , 2012, International journal of radiation oncology, biology, physics.

[6]  Kathleen S. Ashton.  Nursing care of patients undergoing isolated limb procedures for recurrent melanoma of the extremity. , 2012, Journal of perianesthesia nursing : official journal of the American Society of PeriAnesthesia Nurses.

[7]  Thomas Rm,et al.  Mohs micrographic surgery. , 1988, Clinical privilege white paper.

[8]  Zeinab Jradi,et al.  Adjuvante Therapie des malignen Melanoms , 2012 .

[9]  D. Schadendorf,et al.  Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. , 2012, European journal of cancer.

[10]  M. Beutel,et al.  Quality of life in melanoma patients during adjuvant treatment with pegylated interferon-α2b: patients' and doctors' views. , 2011, European journal of dermatology : EJD.

[11]  C. Augustine,et al.  Current trends in regional therapy for melanoma: lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. , 2011, Journal of the American College of Surgeons.

[12]  R. Dufresne,et al.  The Operative Management of Melanoma: Where Does Mohs Surgery Fit In? , 2011, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[13]  E. Paul,et al.  Axillary lymph node dissection for malignant melanoma , 2011, ANZ journal of surgery.

[14]  S. Mocellin,et al.  The Impact of Surgery on Survival of Patients With Cutaneous Melanoma: Revisiting the Role of Primary Tumor Excision Margins , 2011, Annals of surgery.

[15]  C. Garbe,et al.  Survival after intratumoral interleukin-2 treatment of 72 melanoma patients and response upon the first chemotherapy during follow-up , 2011, Cancer Immunology, Immunotherapy.

[16]  M. Hočevar,et al.  Melanoma metastases to the neck nodes: role of adjuvant irradiation. , 2010, International journal of radiation oncology, biology, physics.

[17]  R. Gutzmer,et al.  Comparison of classification systems in melanoma sentinel lymph nodes—An analysis of 697 patients from a single center , 2010, Cancer.

[18]  L. de la Cruz-Merino,et al.  Isolated limb perfusion for malignant melanoma: systematic review on effectiveness and safety. , 2010, The oncologist.

[19]  S. Mocellin,et al.  Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. , 2010, Journal of the National Cancer Institute.

[20]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Ballo,et al.  The benefits of adjuvant radiation therapy after therapeutic lymphadenectomy for clinically advanced, high‐risk, lymph node‐metastatic melanoma , 2009, Cancer.

[22]  M. Mihm,et al.  Expert opinion in melanoma: the sentinel node; EORTC Melanoma Group recommendations on practical methodology of the measurement of the microanatomic location of metastases and metastatic tumour burden. , 2009, European journal of cancer.

[23]  M. Lens,et al.  Surgical excision margins for primary cutaneous melanoma. , 2009, The Cochrane database of systematic reviews.

[24]  I. V. D. van der Ploeg,et al.  Comparison of Three Micromorphometric Pathology Classifications of Melanoma Metastases in the Sentinel Node , 2009, Annals of surgery.

[25]  G. Arcangeli,et al.  Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology , 2009, International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group.

[26]  A. Hauschild,et al.  Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial , 2008, The Lancet.

[27]  A. Hauschild,et al.  EORTC Melanoma Group. Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. , 2008 .

[28]  K. Delman,et al.  Therapy for unresectable recurrent and in-transit extremity melanoma. , 2008, Cancer control : journal of the Moffitt Cancer Center.

[29]  A. Hauschild,et al.  Practical guidelines for the management of interferon‐α‐2b side effects in patients receiving adjuvant treatment for melanoma , 2008, Cancer.

[30]  K. Vosteen,et al.  Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF) , 1992, Unfallchirurgie.

[31]  D. Schadendorf,et al.  Chemoimmunotherapy for cutaneous melanoma with dacarbazine and epifocal contact sensitizers: results of a nationwide survey of the German Dermatologic Co-operative Oncology Group , 2007, Journal of Cancer Research and Clinical Oncology.

[32]  Jeffrey E. Lee,et al.  Randomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  J. Grob,et al.  Randomized Controlled Study of Electrochemotherapy in the Local Treatment of Skin Metastases of Melanoma , 2006, Journal of cutaneous medicine and surgery.

[34]  A. Eggermont,et al.  Isolated Limb Perfusion Prolongs the Limb Recurrence-Free Interval After Several Episodes of Excisional Surgery for Locoregional Recurrent Melanoma , 2004, Annals of Surgical Oncology.

[35]  S. Lo,et al.  Lymphedema After Complete Axillary Node Dissection for Melanoma: Assessment Using a New, Objective Definition , 2004, Annals of surgery.

[36]  D. Neuberg,et al.  Mature results of a phase III randomized trial of bacillus Calmette–Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I–III melanoma (E1673) , 2004, Cancer.

[37]  C. Mélot,et al.  Interferon Alpha as Adjuvant Postsurgical Treatment of Melanoma: A Meta-Analysis , 2004, Dermatology.

[38]  H. Kerl,et al.  Locoregional Cutaneous Metastases of Malignant Melanoma and their Management , 2004, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].

[39]  D. Schadendorf,et al.  Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. , 2004, European journal of cancer.

[40]  M. Möhrle.  Mikrographisch kontrollierte Chirurgie (3D‐Histologie) beim Melanom , 2003 .

[41]  M. Möhrle.  [Micrographic controlled surgery (3D-histology) in cutaneous melanoma]. , 2003, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[42]  C. Garbe,et al.  Phase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastases , 2003, British Journal of Cancer.

[43]  M. Gore,et al.  Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. , 2003, Cancer treatment reviews.

[44]  T. Calcaterra,et al.  Efficacy of radiation therapy in the local control of desmoplastic malignant melanoma , 2003, Head & neck.

[45]  G Rassner,et al.  Metastatic pathways and time courses in the orderly progression of cutaneous melanoma , 2002, The British journal of dermatology.

[46]  R. Dummer,et al.  A retrospective study of 150 patients with lentigo maligna and lentigo maligna melanoma and the efficacy of radiotherapy using Grenz or soft X‐rays , 2002, The British journal of dermatology.

[47]  M. Lens,et al.  Elective lymph node dissection in patients with melanoma: systematic review and meta-analysis of randomized controlled trials. , 2002, Archives of surgery.

[48]  V. Sondak,et al.  High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[49]  D Miklavcic,et al.  Electrochemotherapy with cisplatin: clinical experience in malignant melanoma patients. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[50]  W. Hohenberger,et al.  Palliative radiotherapy for recurrent and metastatic malignant melanoma: prognostic factors for tumor response and long-term outcome: a 20-year experience. , 1999, International journal of radiation oncology, biology, physics.

[51]  A. Eggermont,et al.  Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: results of a multicenter randomized phase III trial. European Organization for Research and Treatment of Cancer Malignant Melanoma Cooperative Group Protocol 18832, the World Health Organization Melanoma Program Trial 15, a , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  A. Hart,et al.  Topical dinitrochlorobenzene combined with systemic dacarbazine in the treatment of recurrent melanoma. , 1997 .

[53]  E. Abemayor,et al.  The role of radiation therapy in the treatment of head and neck cutaneous melanoma. , 1993, American journal of otolaryngology.

[54]  V. Ho,et al.  Pooled analysis of the efficacy of bacille Calmette-Guerin (BCG) immunotherapy in malignant melanoma. , 1993, The Journal of dermatologic surgery and oncology.

[55]  G. Rassner,et al.  [Intralesional therapy of melanoma metastases with recombinant interferon-beta]. , 1992, Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete.

[56]  R. Elashoff,et al.  Improved Long-term Survival After Lymphadenectomy of Melanoma Metastatic to Regional Nodes , 1991 .

[57]  H. Deicher,et al.  Intralesional interferon‐alpha therapy in advanced malignant melanoma , 1988, Cancer.

[58]  J. Hanley,et al.  Double blind randomized prospective trial of levamisole/placebo in stage I cutaneous malignant melanoma. , 1987, Clinical and investigative medicine. Medecine clinique et experimentale.

[59]  N. Cascinelli,et al.  A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma , 1982 .

[60]  Mcbride Cm,et al.  Excision of underlying fascia with a primary malignant melanoma: effect on recurrence and survival rates. , 1982 .

[61]  S. Moss,et al.  DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) surgical adjuvant study COG PROTOCOL 7040 , 1981, Cancer.